Draegerwerk AG & Co KGaA
XBER:DRW8

Watchlist Manager
Draegerwerk AG & Co KGaA Logo
Draegerwerk AG & Co KGaA
XBER:DRW8
Watchlist
Price: 56.4 EUR
Market Cap: €1.1B

Draegerwerk AG & Co KGaA
Investor Relations

Draegerwerk makes medical and safety equipment used in hospitals, emergency rooms, industrial sites, and fire services. In healthcare, it sells anesthesia machines, ventilators, patient monitors, neonatal care equipment, and hospital gas systems. In safety, it sells gas detectors, breathing protection, and devices for testing alcohol and drugs. Its main customers are hospitals, clinics, ambulance services, fire departments, industrial plants, and public safety organizations. Draeger earns money by selling this equipment, along with service, maintenance, spare parts, and consumables that keep the devices working and compliant. That makes its business less like a one-time product seller and more like a long-term supplier tied to installed equipment. What sets Draeger apart is that it sits in two demanding niches where reliability matters a lot: life-supporting medical devices and worker protection equipment. Its products are used in settings where mistakes can be dangerous, so customers tend to value technical expertise, regulatory know-how, and ongoing support. This gives the company a role as a specialized equipment provider rather than a broad healthcare or industrial manufacturer.

Show more
Loading...
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q1 2026
Call Date
Apr 30, 2026
AI Summary
Q1 2026

Strong quarter: Dräger reported continued good demand, with order intake up to around EUR 865 million and net sales back to growth at around EUR 756 million.

Profitability up: EBIT rose sharply to roughly EUR 18 million, lifting the EBIT margin to 2.4% from 0.1% a year ago, helped by a better gross margin and lower expenses.

Cash flow improved: Free cash flow increased to more than EUR 44 million, supported by higher earnings and working-capital discipline.

Outlook kept: Management confirmed full-year guidance for 1% to 5% net sales growth, or 2% to 6% excluding currency effects, and an EBIT margin of 5% to 7.5%.

Regional mix: Growth was led by the Americas and Germany, while APAC was slightly weaker across both divisions.

Macro note: Management said U.S. tariff effects should remain similar to 2025 and that the war against Iran has not had a material impact so far.

Key Financials
Order intake
around EUR 865 million
Net sales
around EUR 756 million
EBIT
roughly EUR 18 million
EBIT margin
2.4%
Free cash flow
more than EUR 44 million
Gross margin
46.3%
Medical order intake
around EUR 480 million
Medical net sales
around EUR 480 million
Medical EBIT
minus EUR 18.5 million
Medical EBIT margin
minus 4.4%
Safety EBIT
around EUR 36 million
Safety EBIT margin
around 11%
Operating cash flow
roughly EUR 62 million
Net financial debt
around EUR 85 million
Net financial debt to EBITDA
0.2
Return on capital employed
15.2%
Net working capital
around EUR 745 million
Equity ratio
around 52%
Other Earnings Calls

Management

Mr. Stefan A. Drager B.A.
Chairman of the Executive Board - Drägerwerk Verwaltungs AG
No Bio Available
Mr. Gert-Hartwig Lescow
CFO, Executive Board Member for IT & Vice Chairman of Executive Board - Drägerwerk Verwaltungs AG
No Bio Available
Mr. Anton Schrofner
Executive Board Member for Medical Division - Drägerwerk Verwaltungs AG
No Bio Available
Mr. Rainer Klug
Executive Board Member for Safety Division - Drägerwerk Verwaltungs AG
No Bio Available
Dr. Reiner Piske
Executive Board Member for Sales & Human Resources - Drägerwerk Verwaltungs AG
No Bio Available
Mr. Thomas Fischler
Head of Treasury & Investor Relations
No Bio Available
Mr. Welf Böttcher
Head of Corporate Communications
No Bio Available

Contacts

Address
SCHLESWIG-HOLSTEIN
Luebeck
Moislinger Allee 53-55
Contacts
+494518820.0
www.draeger.com
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett